Recruitment - Articles

Its hard gaining entry into the pharmaceutical industry, but is it harder if you are thirty? I’m a graduate, so I can get in like a graduate, can’t I?
The possibility of age discrimination within the pharmaceutical industry (clinical trials at least), first occurred through application and interview feedback, such as ‘What year did you graduate?’ and ‘You’ve been out of the industry for too long’. The fact I had been in it at all should have been an advantage over a graduate who hadn’t, particularly as I am applying for graduate entry jobs. There I was thinking removing dates from my CV would be enough to avoid age discrimination, but it just meant any feedback showing age concerns is more polite. What is it that makes age a factor in recruitment, particularly at entry level and what is a…

The results of an in-depth survey of over 750 patients across Europe launched today points to a crisis in the management of the rising numbers of people living in the ‘twilight zone’ of type 2 diabetes care.
IDF Europe, Brussels, April 17th 2007, 12.01AM: The results of an in-depth survey of over 750 patients across Europe launched today points to a crisis in the management of the rising numbers of people living in the ‘twilight zone’ of type 2 diabetes care. They are inadequately controlled on oral antidiabetics but under a false sense of security about the severity of their disease.1 The survey revealed that over three-quarters of patients across Europe wrongly believe their poorly controlled condition is well managed and almost half believe that they have ‘mild’ diabetes.1 The Choose C…

After a year or so of relatively disappointing results from Big Pharma, there seems to be a new wave of optimism sweeping across the industry.
In the past few days we have seen Merck and Schering-Plough announce results ahead of expectations, and now Wyeth joins the club too, with Q1 revenues up by 11%, earnings per share up 12%, and its Pharmaceuticals, Consumer Healthcare and Animal Health segments all hitting double-digit net revenue growth. Commenting on the results, Robert Essner, Chairman and Chief Executive Officer said “Wyeth’s financial performance in the 2007 first quarter was again outstanding. On top of that, the Company added momentum to our new product pipeline by successfully completing a number of important clinical trials for Pristiq for vasomotor symptoms and depressio…

Infusion-related reactions occur with a wide variety of therapeutic agents used in the treatment of cancer but have become a particular concern of the targeted monoclonal antibody therapies. A post-hoc analysis performed on data from a recent large study suggests a way of minimising risk.
Infusion-related reactions occur with a wide variety of therapeutic agents used in the treatment of cancer but have become a particular concern of the targeted monoclonal antibody therapies. A post-hoc analysis performed on data from a recent large study suggests a way of minimising risk. A simple means to help avoid the complication of infusion-related reactions (IRR) affecting patients receiving monoclonal antibody treatments, has been identified in MABEL, a major European open-label study of metastat…

The Appendage of the letter "i" to a word as an aim to create an icon is silly…
The Appendage of the letter "i" to a word as an aim to create an icon is silly… momentary, short-term fame and glory may be possible, but to create a long lasting, global, iconic mark is very doubtful. What makes an icon is also the exclusive longevity of its unique name, and for that reason, you have examples of Rolex and not iWatch, Panasonic and not iTV Terms like, interactive- portable- device were behind creating the name iPod, and has now become responsible for the race for the letter "i" to be ingrained in just about every product category, from: iCell, iCar, iBank to iBrick and just about every word including iCopy. Feeble minds somehow gravitate towards the copying process and feel secure by joining…

Thrombocytopenia, the bleeding disorder caused by a deficiency of platelets, has no easy-to-administer or satisfactory treatment at present. However, eltrombopag (Promacta) a new oral drug in development by GlaxoSmithKline (GSK) has progressed to phase III
Thrombocytopenia, the bleeding disorder caused by a deficiency of platelets, has no easy-to-administer or satisfactory treatment at present. However, eltrombopag (Promacta) a new oral drug in development by GlaxoSmithKline (GSK) has progressed to phase III following encouraging early results regarding efficacy and tolerability. Latest results of a phase II study were presented at the annual American Society of Hematology (ASH) meeting in Orlando, Florida. Patients with too few circulating platelets (thrombocytes) experience problems wi…

With drug pipelines yielding fewer blockbusters and profits from branded drugs being increasingly eroded by generic incursion, pharmaceutical companies are looking to maximize the return on investment of their drugs that do make it to market. Consequently, reformulation has become a common defense by drug makers to prolong the lifecycle of their top sellers.
Pharma turns to reformulation to maximize ROI Reformulation is a popular method of lifecycle management. In fact, from 2002-2005, 39% of the total product launches from the 50 top manufacturers were reformulations. However, before embarking on a reformulation strategy companies must weigh-up whether it is appropriate to commit the required R&D, sales and marketing resources to the project, as opposed to dedicating them to the deve…

AstraZeneca's third biggest-selling drug, Toprol XL, has come up against generic competition sooner than anticipated after losing its protection against copycat launches. AstraZeneca has responded by reaching an agreement with US generic firm Par Pharmaceutical to distribute and supply a 25mg generic version of Toprol XL, a strategy that could be used with its other drugs facing patent expiry.
Toprol XL was originally launched by AstraZeneca in 2001 for the once-daily treatment of hypertension, with the patent protecting the drug expected to expire in September 2007. However, in January 2006, a US district court ruled the patents covering Toprol XL extended-release tablets to be invalid and unenforceable. Following the verdict, Novartis-owned Eon Labs launched a 25mg generic version of the…

Recognizing excellence in the application of an e-business approach in pharma and biotech HR in Europe.
PharmiWeb Solutions is pleased to announce that is now accepting entries for its inaugural PharmiWeb.com e:HR award. This will be an annual award, to be  given in recognition of the best e-business initiative relating to human resources in the pharmaceutical and biotech sector.  This could include innovative use of web-based  recruitment and selection, intranet-based solutions for training and development, or some other novel e-business application in the Human Resources environment. The winning entry will embody technology leadership, and return on investment, and will demonstrate how effective e-business deployment can help bring about positive organisational change. The…

It’s another Monday practice meeting, the usual drug representative has been roped in to provide lunch and is cooling her heels waiting for the team to finish morning surgery. The usual non-descript pile of sandwiches from the local bakery is stacked on the table and the registrar who has finished early has already picked the best sandwiches...
The registrar has struck up a good conversation with her and she thinks that she is onto a winner with this bright eyed and enthusiastic young doctor (little does she know that he is looking for material for the next Vocational Training Scheme session to pick over and analyse to look at the techniques used by drug reps to sell drugs). Time is ticking by and the partner from the other site who often runs half an hour late has not made it – the reps 30…

From October 1st 2006 the Employment Equality (Age) Regulations 2006 - is coming in to force, making it illegal in the UK to recruit or select candidates based on their age and to discriminate based on age whilst in employment rather than based on skills and competencies. This will apply to discrimination againt young and old, and it WILL dramatically affect recruitment and employment in the UK.
Here is a quick round up of the main points from the Regulations  According to the Employers Forum on Age: "More generally, employers must audit carefully their recruitment advertising and procedures. For example, minimum requirements for experience or qualifications are likely to constitute indirect discrimination against younger persons - employers in most cases should therefore avoid langu…

A new DPP-4 inhibitor class of oral anti-diabetic medicines, working by the novel mechanism of incretin enhancement, is poised to revolutionise the management of Type 2 diabetes. Data presented at a recent European Association for the Study of Diabetes meeting suggest they will help fill the unmet need for effective anti-diabetic drugs without unacceptable side effects. Numerous agents are in development with two, Galvus (vildagliptin, Novartis) and Januvia (sitagliptin, Merck) awaiting approval
Type 2 diabetes already affects 230 million people and is rising at epidemic levels with a worldwide prevalence of 350 million forecast for 2025. The global population is getting progressively older and more obese, even in developing countries, and that increases cases of Type 2 disease with their a…

Rapra Technology’s First International Conference on Silicone Elastomers took place in Frankfurt on 19-20 September attracting over 120 delegates from as far away as Australia, Brazil, Russia and the US. Presentations covered silicone elastomer materials, liquid silicone rubber, the processing of silicone elastomers, additives and finishing for silicone elastomers. Delegates praised the breadth of the programme content and the practical nature of many of the papers.
International Conference on Silicone Elastomes Highlights Future Growth Rapra Technology’s First International Conference on Silicone Elastomers took place in Frankfurt on 19-20 September attracting over 120 delegates from as far away as , , and the . Presentations covered silicone elastomer materials, liquid silicone rubber,…

The Hellenic Competition Committee has issued GSK with a favorable decision, indicating that it can restrict the supply of pharmaceuticals to wholesalers to prevent parallel importation of these drugs, without breaking competition laws. This is an important step for legally restricting parallel importation from one of Europe's biggest parallel trade markets, as Datamonitor's Dr Mark Belsey discovers…
In November 2000, Glaxo Wellcome (now GlaxoSmithKline), imposed restrictions on wholesalers' supply of three of its drugs, Imigran (sumatriptan), Lamictal (lamotrigine) and Serevent (salmeterol) in the Greek market. Parallel importation of these drugs was known to take place, whereby these drugs were purchased at a low price in the Greek market and then exported out of the country and into Eu…

Running clinical trials and recruiting experienced clinical personnel in the UK has certainly challenged many senior managers and recruiters over the past year. At a recent UK conference, both the Association of the British Pharmaceutical Industry (ABPI) and a UK pharmaceutical website were quoted as stating that there continues to be a skills shortage across all disciplines; a lack of long-term educational investment and less development of the existing talent pool were cited as the main reaso
Running clinical trials and recruiting experienced clinical personnel in the UK has certainly challenged many senior managers and recruiters over the past year. At a recent UK conference, both the Association of the British Pharmaceutical Industry (ABPI) and a UK pharmaceutical website were quoted a…

Strategic Research Institute’s Phase IV Clinical Trials (PCT) conference features a fully packed informational two day event organized into a series of discussions focusing on the major Phase IV and Patient Recruitment/ Retention issues of today.
Strategic Research Institute’s Phase IV Clinical Trials (PCT) conference features a fully packed informational two day event organized into a series of discussions focusing on the major Phase IV and Patient Recruitment/ Retention issues of today. Some of the topics include the following: Selecting and Qualifying Investigators Key Drivers & Growth Opportunities in Phase IV Trials Patient Recruitment & Retention Effective Use of Technology for Data Collection and Analysis Optimizing Your Post-Marketing Clinical Research The Phase…

GAIN VALUABLE INSIGHT INTO: • How CMS’ movement toward P4P will Impact Healthcare and Payors Nationwide • Large Employer HR Strategy: How Aligning Incentives and Creating a Health • Information Exchange will Reduce your Healthcare Spend • Health Plans: How Data, Transparency and Consumers will Affect your P4P Initiatives
Pay for Performance in Healthcare: Strategies for Achieving Value & Improving Health Outcomes has been designed as the perfect forum for thought leaders in pay for performance and value-driven healthcare to convene and share critical perspectives on the current status and future of P4P. A dynamic mix of speakers, panels and case studies will provide the forum for interactive discussion and issue dialogue. Please join us in November 13-14 for this exciting even…

Highlights Include: Five Presentations from CMS including an Update on the 2007 Landscape Understanding the Short- and Long-Term Impact of Part D Strategies for Driving Senior Enrollment Innovative Approaches to Public & Private Partnerships Analyzing Patient Perceptions of Out-of-Pocket Costs The Importance of Pharmacoeconomic Data Securing Favorable Formulary Coverage in the Part D Environment The Future of Employer Plans
Please join your colleagues to discuss what the Part D market looks like today, how things could change in the future, and some of the critical short- and long-term considerations for all stakeholders including pharmaceutical and biotech marketers, managed care organizations (MCOs), pharmacy benefit managers (PBMs), and CMS. Highlights Include: Five…

i3 Pharma Resourcing focuses on the provision of high calibre clinical research personnel to the pharmaceutical industry, via our permanent and contract resourcing services. If you have recently been involved in the recruitment of clinical research staff, you will be aware that there continues to be a shortage of trained, experienced CRAs. With pressures on both human and financial resources throughout the industry, new staff are required to “hit the ground running”.
Background for clients i3 Pharma Resourcing focuses on the provision of high calibre clinical research personnel to the pharmaceutical industry, via our permanent and contract resourcing services. If you have recently been involved in the recruitment of clinical research staff,  you will be aware that there continues t…

We would like to invite you to join us here at our offices in Maidenhead, Berkshire from 10.30 onwards to 14.30.
Saturday 9th September 2006, i3 are opening our doors from 10.30…………. We would like to invite you to join us here at our offices in Maidenhead, from 10.30 onwards to 14.30. You will have the chance to meet our experienced recruitment team for both internal i3 opportunities and opportunities with our Pharma Resourcing division. Please bring along your questions and an updated CV, should you be interested. We will also be holding a number of presentations during this time. We cover a number of areas…. Clinical Research Associates Data Management Project Managers Clinical Trials Administrators Finance Entry- level opportunities (partnership training course) Quality Assuran…